Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non–Small Cell Lung Cancer

In this phase 2 study, we evaluated the activity of AUY922 in pretreated patients with stage IV NSCLC. Patients with advanced NSCLC were divided into molecularly defined strata based on mutations in the EGFR gene, the ALK receptor tyrosine kinase gene (ALK), the KRAS gene, or the wild type of all th...

Full description

Saved in:
Bibliographic Details
Published in:Journal of thoracic oncology 2018-04, Vol.13 (4), p.576-584
Main Authors: Felip, Enriqueta, Barlesi, Fabrice, Besse, Benjamin, Chu, Quincy, Gandhi, Leena, Kim, Sang-We, Carcereny, Enric, Sequist, Lecia V., Brunsvig, Paal, Chouaid, Christos, Smit, Egbert F., Groen, Harry J.M., Kim, Dong-Wan, Park, Keunchil, Avsar, Emin, Szpakowski, Sebastian, Akimov, Mikhail, Garon, Edward B.
Format: Article
Language:English
Subjects:
ALK rearrangement
AUY922
EGFR mutation
HSP90 inhibitor
KRAS mutation
NSCLC
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this phase 2 study, we evaluated the activity of AUY922 in pretreated patients with stage IV NSCLC. Patients with advanced NSCLC were divided into molecularly defined strata based on mutations in the EGFR gene, the ALK receptor tyrosine kinase gene (ALK), the KRAS gene, or the wild type of all three. All patients must have received more than two prior lines of therapy, except for those in a fifth stratum for a less pretreated EGFR cohort (EGFR
ISSN:1556-0864
1556-1380
DOI:10.1016/j.jtho.2017.11.131